Open AccessTreatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
Author(s) -
Ana Lorena Sousa de Vasconcelos Garate,
Thiara Barcelos Rocha,
Luciana Rocha Almeida,
Rodrigo Quera,
Jaqueline Ribeiro de Barros,
Júlio Pinheiro Baima,
Rogério Saad-Hossne,
Lígia Yukie Sassaki
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i13.3219
Subject(s) - medicine , infliximab , ulcerative colitis , regimen , gastroenterology , trough concentration , trough level , trough (economics) , tumor necrosis factor alpha , pharmacokinetics , disease , transplantation , tacrolimus , economics , macroeconomics
Acute severe ulcerative colitis (ASUC) is a complication of ulcerative colitis associated with high levels of circulating tumor necrosis factor alpha, due to the intense inflammation and faster stool clearance of anti-tumor necrosis factor drugs. Dose-intensified infliximab treatment can be beneficial and is associated with lower rates of colectomy. The aim of the study was to present a case of a patient with ASUC and megacolon, treated with hydrocortisone and accelerated scheme of infliximab that was monitored by drug trough level.